IN2014DN06169A - - Google Patents

Info

Publication number
IN2014DN06169A
IN2014DN06169A IN6169DEN2014A IN2014DN06169A IN 2014DN06169 A IN2014DN06169 A IN 2014DN06169A IN 6169DEN2014 A IN6169DEN2014 A IN 6169DEN2014A IN 2014DN06169 A IN2014DN06169 A IN 2014DN06169A
Authority
IN
India
Prior art keywords
salts
compositions
methods
cyclic compounds
certain fused
Prior art date
Application number
Other languages
English (en)
Inventor
Changyou Zhou
Bo Ren
Hexiang Wang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IN2014DN06169A publication Critical patent/IN2014DN06169A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN6169DEN2014 2011-12-31 2011-12-31 IN2014DN06169A (enEXAMPLES)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/085148 WO2013097225A1 (en) 2011-12-31 2011-12-31 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN06169A true IN2014DN06169A (enEXAMPLES) 2015-08-21

Family

ID=48696280

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6169DEN2014 IN2014DN06169A (enEXAMPLES) 2011-12-31 2011-12-31

Country Status (29)

Country Link
US (4) US9260440B2 (enEXAMPLES)
EP (2) EP2797921B1 (enEXAMPLES)
JP (1) JP6034877B2 (enEXAMPLES)
KR (1) KR101716012B1 (enEXAMPLES)
CN (2) CN103703004B (enEXAMPLES)
AU (1) AU2011384858B2 (enEXAMPLES)
BR (1) BR112014012628B8 (enEXAMPLES)
CA (1) CA2856309C (enEXAMPLES)
CY (1) CY1119804T1 (enEXAMPLES)
DK (1) DK2797921T3 (enEXAMPLES)
EA (1) EA027533B1 (enEXAMPLES)
ES (1) ES2645814T3 (enEXAMPLES)
HR (1) HRP20171883T1 (enEXAMPLES)
HU (1) HUE035153T2 (enEXAMPLES)
IL (1) IL233365A (enEXAMPLES)
IN (1) IN2014DN06169A (enEXAMPLES)
LT (1) LT2797921T (enEXAMPLES)
ME (1) ME02855B (enEXAMPLES)
MX (1) MX353578B (enEXAMPLES)
NO (1) NO2797921T3 (enEXAMPLES)
NZ (1) NZ624063A (enEXAMPLES)
PL (1) PL2797921T3 (enEXAMPLES)
PT (1) PT2797921T (enEXAMPLES)
RS (1) RS56616B1 (enEXAMPLES)
SG (1) SG11201401726VA (enEXAMPLES)
SI (1) SI2797921T1 (enEXAMPLES)
SM (1) SMT201700543T1 (enEXAMPLES)
WO (1) WO2013097225A1 (enEXAMPLES)
ZA (1) ZA201405560B (enEXAMPLES)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2645814T3 (es) 2011-12-31 2017-12-07 Beigene, Ltd. Dihidrodiazepinocarbazolonas tetra o penta-cíclicas condensadas como inhibidores de PARP
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
BR112018003634B1 (pt) 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
ES2991862T3 (es) 2016-04-01 2024-12-05 Recurium Ip Holdings Llc Moduladores del receptor de estrógeno
EP3519051B1 (en) * 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
WO2018157794A1 (en) * 2017-02-28 2018-09-07 Beigene, Ltd. Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof
CN106883232B (zh) * 2017-03-31 2019-01-22 苏州康润医药有限公司 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCERS USING A COMBINATION INCLUDING PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
WO2019228499A1 (en) * 2018-06-01 2019-12-05 Beigene, Ltd. Maintenance therapy of a parp inhibitor in treating gastric cancer
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法
CN111171002B (zh) * 2019-05-16 2021-04-06 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的制备方法
KR20220016028A (ko) 2019-05-31 2022-02-08 베이진 엘티디 Parp 억제제 펠릿 제조 및 이의 제조방법
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445326B (sv) 1983-04-05 1986-06-16 Malmstroem Anders E H Sett och anordning for forhindrande av veggturbulens
US6799298B2 (en) 1998-03-11 2004-09-28 Overture Services, Inc. Technique for locating an item of interest within a stored representation of data
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
CA2430363C (en) 2000-12-01 2010-04-13 Guilford Pharmaceuticals Inc. Compounds and their uses
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
US6906096B2 (en) 2002-06-28 2005-06-14 Irm Llc 4,7-Disubstituted indoles and methods of making
KR100697746B1 (ko) * 2003-01-09 2007-03-22 화이자 인코포레이티드 키나제 저해제로서의 디아제피노인돌 유도체
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
RU2409361C2 (ru) 2006-04-04 2011-01-20 Пфайзер Продактс Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ (2R,Z)-2-АМИНО-2-ЦИКЛОГЕКСИЛ-N-(5-(1-МЕТИЛ-1Н-ПИРАЗОЛ-4-ИЛ)-1-ОКСО-2,6-ДИГИДРО-1Н-[1,2]ДИАЗЕПИНО[4,5,6-cd]ИНДОЛ-8-ИЛ)АЦЕТАМИДОМ
WO2007113647A1 (en) 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
NZ585395A (en) 2007-11-15 2012-03-30 Angeletti P Ist Richerche Bio Pyridazinone derivatives as parp inhibitors
PT2767537T (pt) * 2008-08-06 2017-07-17 Medivation Technologies Inc Inibidores de di-hidropiridoftalazinona de poli(adp-ribose)polimerase (parp)
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
ES2645814T3 (es) 2011-12-31 2017-12-07 Beigene, Ltd. Dihidrodiazepinocarbazolonas tetra o penta-cíclicas condensadas como inhibidores de PARP
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
BR112018003634B1 (pt) 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
WO2018157794A1 (en) 2017-02-28 2018-09-07 Beigene, Ltd. Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof
EP3654985A4 (en) 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCERS USING A COMBINATION INCLUDING PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY

Also Published As

Publication number Publication date
US9617273B2 (en) 2017-04-11
US20160159811A1 (en) 2016-06-09
JP6034877B2 (ja) 2016-11-30
BR112014012628A2 (pt) 2017-06-13
IL233365A (en) 2016-08-31
US9260440B2 (en) 2016-02-16
BR112014012628B8 (pt) 2023-01-17
NZ624063A (en) 2016-09-30
HUE035153T2 (en) 2018-05-02
CY1119804T1 (el) 2018-06-27
EP2797921B1 (en) 2017-09-06
IL233365A0 (en) 2014-08-31
US20150175617A1 (en) 2015-06-25
ME02855B (me) 2018-04-20
EA027533B1 (ru) 2017-08-31
ZA201405560B (en) 2017-02-22
ES2645814T3 (es) 2017-12-07
SG11201401726VA (en) 2014-10-30
EP2797921A4 (en) 2015-10-21
AU2011384858B2 (en) 2016-05-05
RS56616B1 (sr) 2018-02-28
PT2797921T (pt) 2017-11-14
AU2011384858A1 (en) 2014-05-29
MX353578B (es) 2018-01-19
WO2013097225A1 (en) 2013-07-04
HRP20171883T1 (hr) 2018-01-12
PL2797921T3 (pl) 2018-02-28
EA201491303A1 (ru) 2014-10-30
DK2797921T3 (en) 2017-10-02
JP2015503526A (ja) 2015-02-02
SI2797921T1 (en) 2018-01-31
MX2014007840A (es) 2014-08-21
CN103703004B (zh) 2016-06-29
SMT201700543T1 (it) 2018-01-11
CA2856309C (en) 2016-06-07
KR101716012B1 (ko) 2017-03-13
CN106220635B (zh) 2019-03-08
EP3315500A1 (en) 2018-05-02
LT2797921T (lt) 2017-11-27
BR112014012628B1 (pt) 2021-02-09
EP3315500B1 (en) 2020-03-18
CA2856309A1 (en) 2013-07-04
NO2797921T3 (enEXAMPLES) 2018-02-03
US10501467B2 (en) 2019-12-10
HK1192233A1 (zh) 2014-08-15
CN106220635A (zh) 2016-12-14
EP2797921A1 (en) 2014-11-05
KR20140107353A (ko) 2014-09-04
US20190016731A1 (en) 2019-01-17
US10112952B2 (en) 2018-10-30
CN103703004A (zh) 2014-04-02
US20170305921A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IN2014DN06169A (enEXAMPLES)
IN2014DN06166A (enEXAMPLES)
IN2015DN00127A (enEXAMPLES)
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
UY34365A (es) Compuestos heterociclicos
IN2014CN02283A (enEXAMPLES)
UY33930A (es) Inhibidores novedosos de quinasas
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY34836A (es) Nuevo organismos
IN2014MN02598A (enEXAMPLES)
IN2014CN02639A (enEXAMPLES)
IN2012DE02913A (enEXAMPLES)
CR20130539A (es) Triazolopiridinas
UY33977A (es) Híbrido de pigmento autoaglutinante.
BR112014003027A2 (pt) formulação herbicida melhorada
EP2825963A4 (en) ESTABLISHMENT OF EXECUTION TIME INSTRUMENTATION REPORTS
UY34158A (es) Composicion herbicida
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
BR112014027219A2 (pt) método
EP2739764A4 (en) ION SOURCE
IN2012DE02933A (enEXAMPLES)
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
BR112014002498A2 (pt) “composição de tratamento oral não aquosa”